The sample was collected by the ITA under the testing authority and results management authority of the International Olympic Committee (IOC) during an In-Competition anti-doping control on 3 August 2024 in Paris, France. The result was reported by the WADA-accredited laboratory of Paris on 5 August 2024.
Pursuant to the athlete’s request, on 8 August 2024 her B-sample was opened and analysed. The athlete attended the process, along with her representative. The B-sample analysis confirmed the presence of furosemide.
The athlete accepted the consequences of her Anti-Doping Rule Violation (ADRV) under the IOC Anti-Doping Rules applicable to the Olympic Games Paris 2024, i.e. (i) the finding of the ADRV, (ii) Ineligibility for the Olympic Games Paris 2024 and (iii) Disqualification of 28th place results in the Women’s Swimming Sprint 100m at the Olympic Games Paris 2024.
The matter is considered as concluded from the perspective of the IOC and has been referred to World Aquatics for a determination of further consequences.
In the Anti-Doping Database we have registered close to 500 athletes who has been sanctioned for an anti-doping rule violation. Out of these, only 13 tested positive for Furosemide.
If María José Ribera Pinto is sanctioned, she will be the first swimmer from Bolivia that we register in the database. She would also be the 10th athlete from Bolivia to be registered.